Doximity Expands AI Capabilities with $63 Million Acquisition of Pathway Medical
In a strategic move to deepen its foothold in AI-driven clinical tools, Doximity announced its acquisition of Montreal-based startup Pathway Medical for $63 million. The deal, finalized in late July, combines Doximity’s established telehealth and networking platform with Pathway’s advanced AI-powered clinical reference technology designed to deliver precise, data-backed medical answers directly to physicians.
Bringing AI-Powered Clinical Insights to Physicians
Pathway Medical has developed one of the most expansive and structured medical datasets, allowing doctors to query complex clinical questions related to treatment guidelines, medications, and ongoing drug trials. This synthesis is powered by cutting-edge AI that scans and interprets vast amounts of medical literature, providing physicians reliable and quickly accessible information at their fingertips.
Doximity, often described as the "LinkedIn for doctors," has served millions of healthcare professionals by enabling them to stay updated on medical news, simplify administrative tasks, and facilitate patient care through telehealth services. Integrating Pathway’s capabilities aims to further transform Doximity into an indispensable clinical decision support system, helping doctors make evidence-based decisions more efficiently.
CEO Jeff Tangney Speaks on the Strategic Acquisition
In an interview, Jeff Tangney, Doximity’s CEO and co-founder, emphasized the rigorous search behind this acquisition: "We hunted high and low and found the best company in AI-driven physician question answering — and surprisingly, it wasn’t in Silicon Valley but in Montreal." This highlights a growing shift where groundbreaking health tech innovation is emerging beyond traditional U.S. tech hubs.
Seamless Integration and Beta Testing Underway
The integration between Doximity and Pathway is already in progress. Thousands of physicians are engaged in beta testing the combined platform, offering real-world feedback to refine this next-generation clinical tool. The move reflects increasing demand among medical professionals for AI technologies that don’t just automate tasks but enhance critical thinking and patient outcomes.
Addressing the Growing Reliance on AI in Healthcare
As patients themselves turn to AI-powered chatbots for health advice, the stakes are higher than ever for trustworthy medical AI solutions. Erroneous information from generic AI systems can lead to dangerous misguidance. Doximity’s investment in Pathway aims to mitigate this risk by ensuring AI answers are anchored in robust clinical evidence and tailored for healthcare professionals.
Echoing this urgency, OpenAI’s CEO, Sam Altman, noted during the recent GPT-5 announcement that health queries represent one of the largest usage categories for ChatGPT, underscoring the sector’s transformative potential and the critical need for accuracy.
Enhancing Doximity GPT with Pathway’s Data Strength
Doximity already offers Doximity GPT, a free AI tool assisting doctors with tasks such as generating insurance letters and summarizing patient records. Dr. Amit Phull, Doximity’s Chief Clinical Experience Officer, explained how Pathway’s "very robust back-end dataset" — linking drug dosages, clinical guidelines, medical literature, and citations — will significantly enhance the reliability and depth of AI-driven clinical support.
Pathway’s model’s impressive performance on the U.S. Medical Licensing Examination with a 96% score further validates its clinical competency and readiness to support practicing physicians.
Market Response and Financial Outlook
Doximity, which went public in 2021, has experienced significant stock growth, climbing roughly 10% year-to-date in 2025 after a 90% surge in 2024. The acquisition announcement and positive quarterly results—showing a 15% revenue increase to $145.9 million and earnings per share surpassing estimates—have buoyed investor confidence, with shares rising about 6% in after-hours trading.
Looking Ahead: Bridging AI and Clinical Practice
By integrating Pathway Medical’s AI-powered knowledge base, Doximity is poised to revolutionize how healthcare professionals engage with technology — transforming the platform from a communication and workflow tool into a critical clinical partner. This acquisition reflects broader healthcare trends emphasizing precision, efficiency, and evidence-driven AI as vital to improving patient care in an increasingly complex medical landscape.
Key Takeaways:
- $63 million acquisition of Pathway Medical strengthens Doximity’s AI offerings.
- Pathway’s dataset is among the largest and most structured in medicine, powering clinical decision-making.
- AI integration currently in beta testing with thousands of doctors, signaling strong demand.
- Raises critical discussions on reliability and safety of AI in healthcare.
- Doximity’s market performance reflects investor optimism in health tech innovation.
Editor’s Note
The Doximity-Pathway Medical acquisition is a clear signal of AI’s expanding role in clinical practice. Yet, it also raises essential questions about balancing AI innovation with patient safety, data transparency, and physician trust. As AI tools become more embedded in decision-making, ongoing evaluation of their impact on medical outcomes and ethical deployment will be crucial. For policymakers and healthcare leaders alike, the convergence of AI and medicine offers both exciting opportunities and complex challenges that demand careful stewardship.
